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C

oagulase-negative staphylococci (CoNS) are normal flora of
the human skin and mucosa. Because they have long been
considered contaminants rather than true clinical pathogens,
there are few systematic studies describing their epidemiology in
human infections. Nonetheless, colonizing CoNS pathogens have
been reported to be responsible for infections in humans, particularly in immunocompromised hosts (1–3) and neonates (4, 5).
Seventy-three percent of all neonatal bacteremia in the United
States is caused by CoNS pathogens (4, 5). In addition, CoNS are
typically resistant to multiple drug classes (3). The clinical presentations for patients infected with CoNS are often distinct from
those caused by Staphylococcus aureus infections, which occur
more commonly in patients on corticosteroid therapy, those undergoing hemodialysis, or those with implanted catheters or prosthetic valves (6). Of the CoNS pathogens, Staphylococcus epidermidis is the most abundant colonizer of human skin and mucous
membranes and is the most common cause of catheter-associated
bloodstream infections (7).
CoNS infections are most commonly treated with glycopeptides, including vancomycin, but there has been increasing concern regarding emerging resistance to these agents (3). Up to 90%
of S. epidermidis strains are now resistant to methicillin, with resistance to aminoglycosides and macrolides noted among hospital-associated strains. Resistance to linezolid also occurs but is
much less frequent (8, 9). Despite hospital-level reports of increasing resistance, there have been few recent national studies describing the prevalence of antibiotic resistance in clinically important
CoNS pathogens. For example, previously reported surveillance
data (10–12) are more than a decade old.
In this study, we examined national trends in antibiotic resistance of clinical CoNS isolates. We paid particular attention to S.
epidermidis isolates obtained from blood specimens in hospitalized patients, given the important role of this pathogen in hospi-
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tal-acquired infections associated with medical devices. Finally,
we compared the resistance patterns in S. epidermidis with the
overall resistance trends in CoNS pathogens and examined the
correlations with antibiotic prescribing patterns.
MATERIALS AND METHODS
Data. We analyzed national trends in the frequency of resistance for S.
epidermidis and all CoNS pathogens (S. saprophyticus, S. lugdunensis, S.
schleiferi, and S. caprae), using antibiotic susceptibility data from The
Surveillance Network (TSN) Database-USA (managed by Eurofins Medinet, Chantilly, VA). TSN is an electronic repository of susceptibility test
results collected from more than 300 microbiology laboratories in the
United States, representing a national sample of isolates tested for resistance. Laboratories were selected to be geographically and demographically representative of hospital and patient characteristics (bed size, age,
race, and sex) in each of the nine U.S. Census Bureau regional divisions
(13, 14). Testing of isolates occurs on-site as part of the routine diagnostic
testing for susceptibility to different antibiotic agents using standards established by the Clinical and Laboratory Standards Institute (CLSI). Data
from TSN have been used extensively to evaluate patterns and trends of
antibiotic drug resistance (13–21).
Our data included CoNS isolates collected from inpatient areas of
health care facilities from January 1999 to June 2012. To assess longitudi-
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Coagulase-negative staphylococci (CoNS) are important bloodstream pathogens that are typically resistant to multiple antibiotics. Despite the concern about increasing resistance, there have been no recent studies describing the national prevalence of
CoNS pathogens. We used national resistance data over a period of 13 years (1999 to 2012) from The Surveillance Network (TSN)
to determine the prevalence of and assess the trends in resistance for Staphylococcus epidermidis, the most common CoNS
pathogen, and all other CoNS pathogens. Over the course of the study period, S. epidermidis resistance to ciprofloxacin and clindamycin increased steadily from 58.3% to 68.4% and from 43.4% to 48.5%, respectively. Resistance to levofloxacin increased
rapidly from 57.1% in 1999 to a high of 78.6% in 2005, followed by a decrease to 68.1% in 2012. Multidrug resistance for CoNS
followed a similar pattern, and this rise and small decline in resistance were found to be strongly correlated with levofloxacin
prescribing patterns. The resistance patterns were similar for the aggregate of CoNS pathogens. The results from our study demonstrate that the antibiotic resistance in CoNS pathogens has increased significantly over the past 13 years. These results are important, as CoNS can serve as sentinels for monitoring resistance, and they play a role as reservoirs of resistance genes that can
be transmitted to other pathogens. The link between the levofloxacin prescription rate and resistance levels suggests a critical
role for reducing the inappropriate use of fluoroquinolones and other broad-spectrum antibiotics in health care settings and in
the community to help curb the reservoir of resistance in these colonizing pathogens.

Trends in Antibiotic Resistance in CoNS

March 2014 Volume 58 Number 3

FIG 1 Percentage of resistant Staphylococcus epidermidis bloodstream isolates
from inpatients, 1999 to 2012. Multidrug resistance (MDR) is defined as resistance to levofloxacin, clindamycin, ciprofloxacin, and oxacillin. Gray zones
represent 95% confidence intervals.

RESULTS

Trend analysis. We evaluated resistance of S. epidermidis isolates
from blood specimens obtained from hospitalized patients during
the study period and compared their resistance patterns with
those for all CoNS pathogens obtained from all clinical sites. Between 1 January 1999 and 30 June 2012, more than 540,000 CoNS
isolates and 80,000 S. epidermidis blood isolates were submitted to
TSN and included in our analysis.
Over the course of the study, resistance of S. epidermidis to
ciprofloxacin, levofloxacin, and clindamycin individually increased, as did the resistance to a multidrug-resistant phenotype
(Fig. 1). However, the patterns of resistance differed among drugs.
Resistance to ciprofloxacin and clindamycin increased from
58.3% (95% confidence interval [CI], 56.8 to 59.8) in 1999 to
68.4% (95% CI, 64.9 to 71.6) in 2012 and from 43.4% (95% CI,
42.1 to 44.8) in 1999 to 48.5% (95% CI, 45.9 to 51.0) in 2012,
respectively. Resistance to levofloxacin exhibited a different pattern. The percentage of isolates resistant to levofloxacin increased
rapidly from 57.1% (95% CI, 54.8 to 59.3) in 1999 to a high of
78.6% (95% CI, 77.4 to 79.7) in 2005, followed by a significant
decrease to 68.1% (95% CI, 65.1 to 70.9) in 2012. Multidrug resistance followed a similar pattern, ranging from 33.6% (95% CI,
31.3 to 36.0) in 1999 to a high of 56.3% (95% CI, 54.4 to 58.2) in
2005 and a subsequent decrease to 41.1% (95% CI, 37.3 to 45.0) in
2012. Oxacillin resistance remained generally constant at ⬃80%
during the study period. Resistance to linezolid was first detected
in 2004, and by 2012 had reached 1.1% (95% CI, 0.6 to 1.9) (see
Fig. S1 in the supplemental material). Resistance to vancomycin
was not observed over the study period.
The positive trends observed for ciprofloxacin and clindamycin were statistically significant (P ⬍ 0.01) by the Mann-Kendall
test for trend. Because of the increase and decrease patterns asso-
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nal trends in resistance, we examined two sets of isolates, (i) all S. epidermidis bacterial isolates for which the isolate source was blood and (ii) all
CoNS isolates regardless of source. The former set reduces the likelihood
of contamination, although without clinical indicators, it cannot be ruled
out. The latter set of isolates forms the full reservoir of CoNS isolates,
which can serve as an important indicator of possible changes in resistance
levels. Isolates were tested for resistance to oxacillin (a proxy for all ␤-lactam antibiotic drugs, including methicillin), ciprofloxacin, clindamycin,
levofloxacin, linezolid, and vancomycin individually. While both ciprofloxacin and levofloxacin are fluoroquinolones and thus have similar
mechanisms of resistance (22), we examined them separately because
levofloxacin has a broader spectrum of activity against Gram-positive
organisms (see, e.g., references 23 and 24) and because differences in their
resistance rates have been noted (25). In addition to defining individual
resistance profiles, we operationally defined isolates as multidrug resistant
if they were resistant to oxacillin, ciprofloxacin, clindamycin, and levofloxacin. Isolates were categorized for resistance according to the CLSI
breakpoint criteria. Between 2004 and 2005, the resistance breakpoints for
levofloxacin were modified; however, no other changes to data collection
or processing methods occurred during the study period. Isolates that had
intermediate resistance were classified as resistant because of the change in
the resistance breakpoints for levofloxacin (the MIC values for resistance
after the change include the intermediate values for the prior years). For
comparison, we also examined the levofloxacin resistance rates in S. aureus (which were subject to the same breakpoint changes) and Escherichia
coli (no breakpoint change) blood isolates using the same methods.
Trend analysis. The resistance rates for each year were calculated as
the proportion of phenotypes resistant to the number of isolates tested.
Confidence intervals (CIs) were calculated by using the Wilson score
method incorporating continuity correction as detailed by Newcombe
(26). The Mann-Kendall test for trend and the Wilcoxon-Mann-Whitney
rank sum test, which tests whether the distribution from the first half of
the study was the same as that from the second half, were used to evaluate
the statistical significance of observed changes in the frequency of resistance. All data analysis was done using Stata version 10 software (Stata
Corp LP, College Station, TX).
Correlation analysis. We also investigated the correlation between the
yearly levofloxacin prescription rate and the percentage of Staphylococcus
epidermidis isolates that were resistant. However, as has often been noted
in the statistical literature, two time series can appear highly correlated
without any statistical significance (or meaningful connection) (21). Accordingly, we used a time series analysis method similar to that of Sun and
colleagues (21), which addresses this issue, to ascertain the statistical correlation. Briefly, we applied the Box-Jenkins approach to fit time-series
data to autoregressive moving average (ARIMA) statistical models. This
method removes the trend from the data and transforms it into a series of
independent, identically distributed random variables. Time series were
differenced, and the best ARIMA model was selected based on the Akaike
information criterion (AIC). The residuals of the model were then diagnosed for acceptability using the Box-Ljung white noise test. The residuals
from prescription and resistance models were then cross-correlated to
examine their association.
Prescription data were obtained from IMS Health’s Xponent database,
which contains the number of dispensed drug prescriptions collected
from retail pharmacies (chains, mass merchandisers, independents, and
food stores) in the United States by month. The database covers ⬎70% of
all prescriptions filled in the United States, and records are then weighted
to project 100% of total prescriptions dispensed. Because the fluoroquinolones may have similar mechanisms of action and thus contribute to
cross-resistance, we examined the correlation between levofloxacin resistance in S. epidermidis infections and both ciprofloxacin and all fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin) prescriptions.
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from inpatients, 1999 to 2012. The CoNS species data include data for S.
epidermidis and S. hominis. The data for these two species are included for
comparison. Gray zones represent 95% confidence intervals.

ciated with levofloxacin resistance, we used the Wilcoxon-MannWhitney rank sum test to determine whether the first half of the
time series was statistically different from the second half. We
found that this difference was statistically significant (P ⬍ 0.01),
indicating highly significant trends in the patterns of resistance
throughout the study period.
The pattern was similar when looking at all CoNS pathogens
and at another common CoNS colonizer, Staphylococcus hominis,
with multidrug resistance reaching a high of 45.3% (95% CI, 44.2
to 46.3%) in 2005 and a low of 29.6% (95% CI, 28.0 to 31.3%) in
2012 (Fig. 2; for more detail, see Tables S1 and S2 in the supplemental material). We also found that antibiotic resistance patterns
varied by U.S. region, with the highest rates of resistance noted for
the Northeast for both S. epidermidis isolates and all CoNS organisms (Fig. 3). Finally, we found that S. aureus isolates followed
increase and decrease patterns similar to those of S. epidermidis,
while Escherichia coli resistance increased rapidly from around 5%
in 1999 to ⬎30% in 2008 before leveling off (see Fig. S2 in the
supplemental material).
Correlation analysis. We further examined the observed pattern of S. epidermidis resistance to levofloxacin because we found
that it was correlated with the levofloxacin prescription rate (Fig.
4). Using time-series analysis, we constructed ARIMA models for
each time series (all models were determined to be acceptable
based on the AIC and Box-Ljung test for white noise of residuals;
for a description of the ARIMA model parameters and diagnostics, see Table S3 in the supplemental data). The ARIMA residuals
for the prescription and resistance time series were then crosscorrelated, and we found positive and significant (P values at or
below the 10% level) cross-correlation coefficients for levofloxacin prescriptions and levofloxacin resistance but not for ciprofloxacin or total fluoroquinolone prescriptions (Table 1; for fluo-
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FIG 3 Regional variations in coagulase-negative staphylococcal resistance. There
were significant variations in the rates of resistance between regions for Staphylococcus epidermidis blood isolates from inpatients (A) and all coagulase-negative species from all sources (B). In particular, the Northeast had high rates of
resistance.

roquinolone prescription trends, see Fig. S3 in the supplemental
data). The results were consistent whether we looked at all S. epidermidis isolates or only at bloodstream isolates. The S. epidermidis bloodstream isolate multidrug resistance rates were also highly
correlated with levofloxacin prescriptions, but rates for all S. epidermidis isolates were not. Multidrug resistance rates were not
correlated with ciprofloxacin or total fluoroquinolone prescriptions (P values not shown). Ciprofloxacin prescriptions were also
not strongly correlated with ciprofloxacin resistance.
DISCUSSION

Infections caused by S. epidermidis are clinically important in
hospitalized patients and play a significant commensal role in the
community. Although previously considered contaminants,
CoNS now account for 20 to 30% of all clinically relevant bloodstream infections and a significant proportion of catheter-related
bloodstream infections (3). Nearly all CoNS strains display methicillin resistance, with 81% demonstrating resistance to multiple
drugs (27). Difficult-to-eradicate bacteremia has also been associated with CoNS infection and biofilm formation (28) and, recently, some S. epidermidis clones (CC2) have been found to display particularly high rates of multidrug resistance. In addition,
rapid development of antibiotic resistance to mupirocin, an agent
used for topical decolonization for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant S. epidermidis,
was described (29). The discovery of plasmid-mediated fluoroquinolone resistance mechanisms (30, 31) makes CoNS resistance
more troubling because the CoNS pathogens are such abundant
colonizers of human skin and mucous membranes. Thus, there
are frequent opportunities for development of resistance that affects the downstream resistance of not only CoNS pathogens but
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FIG 2 Percentage of all resistant coagulase-negative Staphylococcus sp. isolates
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also other bacteria, such as MRSA (32–34), a pathogen which is
estimated to be responsible for more than 400,000 hospitalizations per year in the United States (35). However, despite the
importance of CoNS as both a marker of drug resistance and a
potential reservoir for resistance genes, there has been no recent
estimate of the magnitude of resistance in CoNS, and our paper is
the first we are aware of that describes longitudinal trends at the
national level.
Consistent with prior reports (10, 12), we found high rates of
resistance to oxacillin and high rates of multidrug resistance.
However, our results also describe significant changes over the last
decade in resistance to levofloxacin, which was observed to have a
significant positive trend through 2005, corresponding to a period
of increase in outpatient levofloxacin prescriptions. The subsequent decrease observed after 2005 was also correlated to a decrease in the volume of levofloxacin prescriptions provided during that time period. Using time-series analysis of prescription
and resistance data, we found strong correlations between levofloxacin prescriptions and both levofloxacin resistance and multidrug resistance rates for S. epidermidis but no significant correlations with ciprofloxacin or total fluoroquinolone prescriptions.
The time-series methods used suggest that the patterns in resistance rates observed are causally related to prescription rates for
levofloxacin, suggesting that decreases in the use of levofloxacin
after 2005 contributed significantly to the changes in the resistance profiles observed. Although cross-resistance with ciprofloxacin is possible and likely played a role as ciprofloxacin prescriptions surged in 2005 as well, our results suggest that the
decrease in levofloxacin prescriptions was the main factor leading
to reductions in resistance. The fact that ciprofloxacin usage did

March 2014 Volume 58 Number 3

TABLE 1 Cross-correlation coefficients between drug-resistant isolates
and levofloxacin prescriptions, 1999 to 2010a

Isolate type and antibiotic prescribed

Crosscorrelation
coefficient

P value

Levofloxacin-resistant Staphylococcus epidermidis
blood isolates
Levofloxacin
Ciprofloxacin
Fluoroquinolone

0.53
0.32
0.48

0.07
0.29
0.11

Levofloxacin-resistant Staphylococcus
epidermidis, all isolates
Levofloxacin
Ciprofloxacin
Fluoroquinolone

0.71
0.31
0.12

⬍0.01
0.29
0.71

0.65

⬍0.02

0.34

0.23

0.33

0.27

⫺0.04

0.90

Multidrug-resistant Staphylococcus epidermidis
blood isolates: levofloxacin
Multidrug-resistant Staphylococcus epidermidis,
all isolates: levofloxacin
Ciprofloxacin-resistant Staphylococcus
epidermidis blood isolates: ciprofloxacin
Ciprofloxacin-resistant Staphylococcus
epidermidis, all isolates: ciprofloxacin

a
Prescription data source, IMS Xponent, January 1999 to December 2010, IMS Health
Incorporated; resistance data source, The Surveillance Network (TSN) Database-USA
(managed by Eurofins Medinet, Chantilly, VA).
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FIG 4 Correlation between levofloxacin drug use and resistance. Levofloxacin
drug use increased significantly between 1999 and 2005, corresponding to a
period of rising resistance rates for S. epidermidis to levofloxacin. As the number of prescriptions fell over the next several years, resistance also fell, although
it did not fall as fast or as far as it rose, and increases in the number of prescriptions in 2012 are associated with increases in resistance rates. (Drug usage
source, IMS Xponent, January 1999 to December 2010, IMS Health Incorporated; resistance data source, The Surveillance Network.)

not seem to play a role in levofloxacin resistance is potentially due
to the fact that levofloxacin has a broader spectrum of activity (23,
24) and equivalent or greater bioavailability, higher plasma concentrations, increased tissue penetration (36), and enhanced penetration of the bacterial cell (37) relative to those for ciprofloxacin.
Alternatively, differences in the activity levels against DNA gyrase
and topoisomerase IV, the primary targets of fluoroquinolones,
may also account for these findings (22). Our results are also consistent with those of other reports showing a link between levofloxacin use and resistance in hospitalized patients (38).
The strong correlation with multidrug-resistant S. epidermidis
rates raises an interesting ecological question for further study. In
particular, this correlation may have occurred because levofloxacin use reduced the fitness costs associated with being resistant to
other drugs. Alternatively, the decline in levofloxacin use may
have been related to the use of another drug(s) that was more
effective against multidrug-resistant strains. This result needs
more study to understand the ecological and epidemiological consequences of exogenous changes in drug usage. The strong relationship between variations in levofloxacin prescriptions and
resistance rates across the years suggests the importance of monitoring CoNS as a valuable surveillance tool. These results also
suggest that antimicrobial stewardship programs that reduce prescription rates are likely to be effective in reducing resistance.
However, the results also point to the strong connection between
community antibiotic use and inpatient resistance rates (21).
Stewardship programs must therefore encompass not just the hospital but the surrounding outpatient care centers as well.
In addition to changes in national resistance levels, we also
describe variations in antibiotic resistance by region. We found
disparities in the community-level antibiotic resistance across the
United States that might lead to disparate downstream regional
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CoNS pathogens. These pathogens are ubiquitous and are associated with serious bacterial infections. The ability to transfer resistance mechanisms to other virulent pathogens, such as S. aureus,
may give CoNS the potential to promote downstream resistance in
other pathogens, although further research is needed to elucidate
this potential. Our findings suggest the need for further surveillance of emerging resistance in CoNS. Better surveillance data are
needed both to advance strategies to reduce the inappropriate use
of fluoroquinolones and other broad-spectrum antibiotics and to
guide the development of new antibacterial agents.
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our resistance trend findings have important implications for human health because of the potential for CoNS to cause clinically
significant infections and promote antibiotic resistance in other
species. Because our data included only outpatient prescriptions,
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between 1999 and 2005, with a subsequent significant downward
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have an important effect on multidrug antibiotic resistance of
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